Browse OPRL1

Summary
SymbolOPRL1
Nameopiate receptor-like 1
Aliases NOCIR; ORL1; OOR; KOR-3; LC132 receptor-like; orphanin FQ receptor; kappa3-related opioid receptor; kappa-ty ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein. Cytoplasmic vesicle. Note=Ligand binding leads to receptor internalization into cytoplasmic vesicles, decreasing the amount of available receptor at the cell surface. Internalization requires phosphorylation at Ser-363. Can recycle to the cell membrane.
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

G-protein coupled opioid receptor that functions as receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception and the perception of pain. Plays a role in the regulation of locomotor activity by the neuropeptide nociceptin.

> Gene Ontology
 
Biological Process GO:0001696 gastric acid secretion
GO:0003013 circulatory system process
GO:0003014 renal system process
GO:0006140 regulation of nucleotide metabolic process
GO:0006164 purine nucleotide biosynthetic process
GO:0006171 cAMP biosynthetic process
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway
GO:0007193 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007218 neuropeptide signaling pathway
GO:0007586 digestion
GO:0007622 rhythmic behavior
GO:0007623 circadian rhythm
GO:0007626 locomotory behavior
GO:0007631 feeding behavior
GO:0008015 blood circulation
GO:0008217 regulation of blood pressure
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009190 cyclic nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0010959 regulation of metal ion transport
GO:0019233 sensory perception of pain
GO:0022600 digestive system process
GO:0022898 regulation of transmembrane transporter activity
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030800 negative regulation of cyclic nucleotide metabolic process
GO:0030802 regulation of cyclic nucleotide biosynthetic process
GO:0030803 negative regulation of cyclic nucleotide biosynthetic process
GO:0030808 regulation of nucleotide biosynthetic process
GO:0030809 negative regulation of nucleotide biosynthetic process
GO:0030814 regulation of cAMP metabolic process
GO:0030815 negative regulation of cAMP metabolic process
GO:0030817 regulation of cAMP biosynthetic process
GO:0030818 negative regulation of cAMP biosynthetic process
GO:0031644 regulation of neurological system process
GO:0031646 positive regulation of neurological system process
GO:0032355 response to estradiol
GO:0032409 regulation of transporter activity
GO:0032410 negative regulation of transporter activity
GO:0032412 regulation of ion transmembrane transporter activity
GO:0032413 negative regulation of ion transmembrane transporter activity
GO:0034762 regulation of transmembrane transport
GO:0034763 negative regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0034766 negative regulation of ion transmembrane transport
GO:0035809 regulation of urine volume
GO:0035810 positive regulation of urine volume
GO:0038003 opioid receptor signaling pathway
GO:0042698 ovulation cycle
GO:0042752 regulation of circadian rhythm
GO:0042755 eating behavior
GO:0043271 negative regulation of ion transport
GO:0044057 regulation of system process
GO:0044058 regulation of digestive system process
GO:0044849 estrous cycle
GO:0045475 locomotor rhythm
GO:0045776 negative regulation of blood pressure
GO:0045980 negative regulation of nucleotide metabolic process
GO:0046058 cAMP metabolic process
GO:0046390 ribose phosphate biosynthetic process
GO:0046717 acid secretion
GO:0048511 rhythmic process
GO:0048512 circadian behavior
GO:0050795 regulation of behavior
GO:0050878 regulation of body fluid levels
GO:0051047 positive regulation of secretion
GO:0051051 negative regulation of transport
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051924 regulation of calcium ion transport
GO:0051926 negative regulation of calcium ion transport
GO:0051930 regulation of sensory perception of pain
GO:0051931 regulation of sensory perception
GO:0052652 cyclic purine nucleotide metabolic process
GO:0055074 calcium ion homeostasis
GO:0060453 regulation of gastric acid secretion
GO:0060454 positive regulation of gastric acid secretion
GO:0060456 positive regulation of digestive system process
GO:0070588 calcium ion transmembrane transport
GO:0070838 divalent metal ion transport
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0072522 purine-containing compound biosynthetic process
GO:1900371 regulation of purine nucleotide biosynthetic process
GO:1900372 negative regulation of purine nucleotide biosynthetic process
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900543 negative regulation of purine nucleotide metabolic process
GO:1901019 regulation of calcium ion transmembrane transporter activity
GO:1901020 negative regulation of calcium ion transmembrane transporter activity
GO:1901293 nucleoside phosphate biosynthetic process
GO:1901385 regulation of voltage-gated calcium channel activity
GO:1901386 negative regulation of voltage-gated calcium channel activity
GO:1903169 regulation of calcium ion transmembrane transport
GO:1903170 negative regulation of calcium ion transmembrane transport
GO:1904058 positive regulation of sensory perception of pain
GO:1904059 regulation of locomotor rhythm
GO:1904062 regulation of cation transmembrane transport
GO:1904063 negative regulation of cation transmembrane transport
GO:2001257 regulation of cation channel activity
GO:2001258 negative regulation of cation channel activity
Molecular Function GO:0001626 nociceptin receptor activity
GO:0001653 peptide receptor activity
GO:0004985 opioid receptor activity
GO:0008022 protein C-terminus binding
GO:0008528 G-protein coupled peptide receptor activity
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0042923 neuropeptide binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04080 Neuroactive ligand-receptor interaction
Reactome R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolOPRL1
Nameopiate receptor-like 1
Aliases NOCIR; ORL1; OOR; KOR-3; LC132 receptor-like; orphanin FQ receptor; kappa3-related opioid receptor; kappa-ty ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between OPRL1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolOPRL1
Nameopiate receptor-like 1
Aliases NOCIR; ORL1; OOR; KOR-3; LC132 receptor-like; orphanin FQ receptor; kappa3-related opioid receptor; kappa-ty ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of OPRL1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolOPRL1
Nameopiate receptor-like 1
Aliases NOCIR; ORL1; OOR; KOR-3; LC132 receptor-like; orphanin FQ receptor; kappa3-related opioid receptor; kappa-ty ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of OPRL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1580.653
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4060.474
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0040.994
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.9530.0411
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.9080.296
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.0240.4
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2580.415
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3650.572
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1820.785
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.170.741
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1170.863
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0480.708
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of OPRL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.11.49.70.0589
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.11.79.40.0895
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolOPRL1
Nameopiate receptor-like 1
Aliases NOCIR; ORL1; OOR; KOR-3; LC132 receptor-like; orphanin FQ receptor; kappa3-related opioid receptor; kappa-ty ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of OPRL1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolOPRL1
Nameopiate receptor-like 1
Aliases NOCIR; ORL1; OOR; KOR-3; LC132 receptor-like; orphanin FQ receptor; kappa3-related opioid receptor; kappa-ty ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of OPRL1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by OPRL1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolOPRL1
Nameopiate receptor-like 1
Aliases NOCIR; ORL1; OOR; KOR-3; LC132 receptor-like; orphanin FQ receptor; kappa3-related opioid receptor; kappa-ty ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of OPRL1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolOPRL1
Nameopiate receptor-like 1
Aliases NOCIR; ORL1; OOR; KOR-3; LC132 receptor-like; orphanin FQ receptor; kappa3-related opioid receptor; kappa-ty ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of OPRL1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolOPRL1
Nameopiate receptor-like 1
Aliases NOCIR; ORL1; OOR; KOR-3; LC132 receptor-like; orphanin FQ receptor; kappa3-related opioid receptor; kappa-ty ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between OPRL1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolOPRL1
Nameopiate receptor-like 1
Aliases NOCIR; ORL1; OOR; KOR-3; LC132 receptor-like; orphanin FQ receptor; kappa3-related opioid receptor; kappa-ty ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting OPRL1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting OPRL1.
ID Name Drug Type Targets #Targets
DB00921BuprenorphineSmall MoleculeOPRD1, OPRK1, OPRL1, OPRM14
DB01497EtorphineSmall MoleculeOPRD1, OPRK1, OPRL1, OPRM1, POMC, TRIM136
DB05492Epicept NP-1Small MoleculeADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, HRH1, HTR2A, HTR2B ......12